Form 4: Singular Genomics CFO Dalen Meeter Reports Stock Transactions

Chief Financial Officer of Singular Genomics Systems, Dalen Meeter, reports the acquisition and disposal of common stock related to vested Restricted Stock Units.

Summary

• Dalen Meeter, the CFO of Singular Genomics Systems, reported a transaction involving the company's common stock on September 15, 2024.
• The transaction involved the settlement of vested Restricted Stock Units (RSUs), with each RSU representing the right to receive one share of common stock.
• Meeter acquired 209 shares of common stock upon the vesting of RSUs.
• Following the reported transaction, Meeter beneficially owns 8,193 shares of common stock.
• The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that Singular Genomics Systems, Inc. effected on June 26, 2024.
• Meeter also holds 2,083 Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the CFO, engages in transactions involving the company's stock. It provides transparency to investors regarding the trading activities of key personnel.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects routine executive compensation.

Key Dates